ATE434447T1 - Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion - Google Patents

Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion

Info

Publication number
ATE434447T1
ATE434447T1 AT99972110T AT99972110T ATE434447T1 AT E434447 T1 ATE434447 T1 AT E434447T1 AT 99972110 T AT99972110 T AT 99972110T AT 99972110 T AT99972110 T AT 99972110T AT E434447 T1 ATE434447 T1 AT E434447T1
Authority
AT
Austria
Prior art keywords
compositions
methods
vessel occlusion
producing vessel
administering
Prior art date
Application number
AT99972110T
Other languages
English (en)
Inventor
Michael Stewart
Roland Person
Antoine Noujaim
Original Assignee
Novolytics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novolytics Inc filed Critical Novolytics Inc
Application granted granted Critical
Publication of ATE434447T1 publication Critical patent/ATE434447T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99972110T 1998-11-12 1999-11-10 Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion ATE434447T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10812998P 1998-11-12 1998-11-12
PCT/IB1999/001809 WO2000029029A1 (en) 1998-11-12 1999-11-10 Compositions and methods for producing vascular occlusion

Publications (1)

Publication Number Publication Date
ATE434447T1 true ATE434447T1 (de) 2009-07-15

Family

ID=22320484

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99972110T ATE434447T1 (de) 1998-11-12 1999-11-10 Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion

Country Status (10)

Country Link
US (4) US6887474B1 (de)
EP (1) EP1131106B1 (de)
JP (1) JP2002529521A (de)
AT (1) ATE434447T1 (de)
AU (1) AU773174B2 (de)
CA (1) CA2348781A1 (de)
DE (1) DE69941031D1 (de)
IL (2) IL142864A0 (de)
RU (1) RU2227752C2 (de)
WO (1) WO2000029029A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
BR9912053A (pt) * 1998-07-13 2001-04-03 Univ Texas Processos de tratamento de câncer utilizando conjugados terapêuticos que se ligam a aminofosfolipìdios
CA2348781A1 (en) * 1998-11-12 2000-05-25 Novolytics Inc. Compositions and methods for producing vascular occlusion
ATE410119T1 (de) 1998-12-01 2008-10-15 Univ Washington Vorrichtung zur intravaskulären embolisierung
CA2459794C (en) * 2001-09-12 2012-08-21 Virexx Medical Corp. Vascular occlusion solid-phase agent with immobilised platelet binding agent
TW200303919A (en) 2001-12-05 2003-09-16 Hiroyuki Ohno Cytotoxic protein and the use
AU2002365844A1 (en) * 2001-12-07 2003-06-17 Antoine Noujaim Compositions and methods for producing vascular occlusion
JP5183010B2 (ja) 2002-05-16 2013-04-17 グリコミメティクス， インコーポレイテッド セレクチンによって媒介される機能を阻害するための化合物および方法
US20040180812A1 (en) * 2002-12-13 2004-09-16 Technology Center Methods of treating and preventing proliferative disease
FR2851211B1 (fr) 2003-02-19 2006-01-13 Faurecia Sieges Automobile Siege rabattable et vehicule comportant un tel siege
DE602004011272T2 (de) 2003-11-19 2008-12-24 Glycomimetics, Inc. Spezifischer antagonist sowohl für e- als auch p-selektine
WO2006002073A2 (en) * 2004-06-15 2006-01-05 Vanderbilt University Method for preventing heme-induced lipid peroxidation
US9155764B1 (en) 2004-12-07 2015-10-13 University Of Miami Expanded utility of red-cell derived microparticles (RMP) for treatment of bleeding
US8105632B2 (en) 2004-12-07 2012-01-31 University Of Miami Cell-derived microparticles as hemostatic agents for control of hemorrhage and treatment of bleeding disorders
US8367669B2 (en) * 2005-06-15 2013-02-05 Vanderbilt University Inhibitors of hemeprotein-catalyzed lipid peroxidation
US9133212B1 (en) 2005-06-15 2015-09-15 Vanderbilt University Inhibitors of hemeprotein-catalyzed lipid peroxidation
WO2007021721A2 (en) 2005-08-09 2007-02-22 Glycomimetics, Inc. Glycomimetic inhibitors of the pa-il lectin, pa-iil lectin or both the lectins from pseudomonas
SI2264043T1 (en) 2005-09-02 2018-01-31 Glycomimetics, Inc. HETEROBIFUNCTIONAL PAN-SELECTINE INHIBITORS
US20070178104A1 (en) * 2006-01-31 2007-08-02 Awdalla Essam T Methods and means for treating solid tumors
WO2007147127A2 (en) * 2006-06-15 2007-12-21 Cook Incorporated Methods, systems, and devices for the delivery of endoluminal prostheses
US7964569B2 (en) 2006-10-12 2011-06-21 Glycomimetics, Inc. Glycomimetic replacements for hexoses and N-acetyl hexosamines
WO2008049056A2 (en) * 2006-10-18 2008-04-24 Baylor College Of Medicine Treatment of medical condition with a2 domain of von willebrand factor
WO2008100453A1 (en) 2007-02-09 2008-08-21 Glycomimetics, Inc. Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines
US8372427B2 (en) 2007-03-05 2013-02-12 Abbott Cardiovascular Systems Inc. Therapeutic composition with enhanced endothelium targeting
US8039442B2 (en) 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
US8617820B2 (en) * 2007-08-28 2013-12-31 Ortho-Clinical Diagnostics, Inc. Use of glycosaminoglycans to reduce non-specific binding in immunoassays
EP2187983B1 (de) * 2007-09-12 2014-04-16 Cook Incorporated Verbessertes umgestaltbares material für den verschluss von körpergefässen
DK2224957T3 (da) * 2007-11-26 2014-01-20 Imbiotechnologies Ltd Sammensætninger og fremgangsmåder til fremkaldelse af vaskulær okklusion under anvendelse af et fast-fase blodplade-bindemiddel
WO2009082014A1 (ja) * 2007-12-25 2009-07-02 Yamaguchi University 薬物送達システム
US8895510B2 (en) 2008-04-08 2014-11-25 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
US8518896B2 (en) 2008-06-13 2013-08-27 Glycomimetics, Inc. Treatment of cancers of the blood using selected glycomimetic compounds
JP2012504961A (ja) 2008-10-06 2012-03-01 ミネルバ バイオテクノロジーズ コーポレーション Ｍｕｃ１＊抗体
CN102802420A (zh) * 2009-04-17 2012-11-28 尼基制药公司 治疗肝癌的方法
AU2010241807B2 (en) 2009-05-01 2014-08-14 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors
US9044454B2 (en) * 2010-03-10 2015-06-02 Northwestern University Regulation of microvasculature occlusion
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
WO2013040507A1 (en) * 2011-09-15 2013-03-21 Omthera Pharmaceuticals, Inc. Methods and compositions for treating, reversing, inhibiting or preventing resistance to antiplatelet therapy
EP2794626B3 (de) 2011-12-22 2020-08-05 GlycoMimetics, Inc. E-selectin-antagonistenverbindungen
HUE038423T2 (hu) 2012-12-07 2018-10-29 Glycomimetics Inc E-szelektin antagonistákat felhasználó vegyületek, készítmények és eljárások vérképzõ sejtek mobilizációjára
KR101552138B1 (ko) * 2012-12-26 2015-09-10 국립암센터 신규한 암 병변 표지용 조성물
WO2015154057A1 (en) * 2014-04-04 2015-10-08 Nhan Tran Methods for treating cancer
AU2015301014B2 (en) * 2014-08-08 2021-05-06 Poseida Therapeutics, Inc. Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors
CN107108679B (zh) 2014-12-03 2020-10-23 糖模拟物有限公司 E-选择蛋白和cxcr4趋化因子受体的异双官能抑制剂
EP3256494A4 (de) 2015-02-10 2018-12-05 Minerva Biotechnologies Corporation Humanisierte anti-muc1*-antikörper
US10456452B2 (en) 2015-07-02 2019-10-29 Poseida Therapeutics, Inc. Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
WO2017127422A1 (en) 2016-01-22 2017-07-27 Glycomimetics, Inc. Glycomimetic inhibitors of pa-il and pa-iil lectins
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
EP3449004B1 (de) 2016-04-29 2021-02-24 Poseida Therapeutics, Inc. Mizellen auf poly(histidin)-basis zur komplexierung und abgabe von proteinen und nukleinsäuren
US11433086B2 (en) 2016-08-08 2022-09-06 Glycomimetics, Inc. Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
BR112019006642A2 (pt) 2016-10-07 2019-07-02 Glycomimetics Inc antagonistas multiméricos de e-selectina altamente potentes
EP3548092B1 (de) 2016-11-30 2022-07-06 University of Miami Rmp-zusammensetzungen und verfahren zur verwendung
CA3054605A1 (en) 2017-03-15 2018-09-20 Glycomimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
AU2018273988C1 (en) 2017-05-26 2025-11-13 Bruin Biosciences, Inc. Chemoembolization agents
EP3717013A1 (de) 2017-11-30 2020-10-07 GlycoMimetics, Inc. Verfahren zur mobilisierung von knochenmarkinfiltrierenden lymphozyten und deren verwendung
US11548908B2 (en) 2017-12-29 2023-01-10 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
AU2019230013A1 (en) 2018-03-05 2020-09-10 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
EP0771216B9 (de) * 1994-07-11 2003-01-02 The Board Of Regents, The University Of Texas System Verfahren und zusammensetzungen für die spezifische koagulation von tumorgefässen
US5763199A (en) * 1994-09-29 1998-06-09 Mount Sinai School Of Medicine Of The City University Of New York Platelet blockade assay
JPH08333400A (ja) * 1995-06-09 1996-12-17 Ajinomoto Co Inc 抗血栓活性を有する融合蛋白質及びその製法
JP2000504934A (ja) * 1995-12-22 2000-04-25 バクスター バイオテク テクノロジー エス．アー．アール．エル． 結合ドメインを含むグロビン
US6132729A (en) * 1997-01-22 2000-10-17 Board Of Regents, The University Of Texas System Combined tissue factor and chemotherapeutic methods and compositions for coagulation and tumor treatment
CA2348781A1 (en) * 1998-11-12 2000-05-25 Novolytics Inc. Compositions and methods for producing vascular occlusion
CA2459794C (en) * 2001-09-12 2012-08-21 Virexx Medical Corp. Vascular occlusion solid-phase agent with immobilised platelet binding agent

Also Published As

Publication number Publication date
US7947282B2 (en) 2011-05-24
RU2227752C2 (ru) 2004-04-27
EP1131106B1 (de) 2009-06-24
US20070098724A1 (en) 2007-05-03
WO2000029029A1 (en) 2000-05-25
US20050287145A1 (en) 2005-12-29
CA2348781A1 (en) 2000-05-25
IL142864A0 (en) 2002-03-10
AU773174B2 (en) 2004-05-20
US7390488B2 (en) 2008-06-24
IL142864A (en) 2007-09-20
EP1131106A1 (de) 2001-09-12
JP2002529521A (ja) 2002-09-10
US6887474B1 (en) 2005-05-03
DE69941031D1 (de) 2009-08-06
AU1171600A (en) 2000-06-05
WO2000029029A9 (en) 2000-11-02
US20020168366A1 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
DE69941031D1 (de) Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion
HU9700084D0 (en) Composition for specific coagulating vascular system
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE521357T1 (de) Verfahren zur behandlung von hepatitis
DE69527847D1 (de) Verwendung von anti-vegf-mitteln zur behandlung der endometriose
MXPA03009408A (es) Factor de crecimiento endotelial vascular 2.
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
PT1782825E (pt) Tratamento de doenças de armazenanto de glicogénio tipo ii
PT998287E (pt) Utilizacao de levobupivacaina
FI972703A0 (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
UA60352C2 (uk) Синтетичні полісахариди та фармацевтична композиція, що їх містить
DE69534620D1 (de) Verfahren zur behandlung von augenerkrankungen
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
ATE291918T1 (de) Kombinationstherapie zur behandlung von tumoren
PL327542A1 (en) Agents capable to bond hialuronic acid receptors and their application
DE60330501D1 (de) Verfahren zur behandlung von verletzungen des nervensystems in verbindung mit einer blutung
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
EP1240900A4 (de) Medizinische zusammensetzungen zur prävention und behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen
DE50108711D1 (de) Verwendung von substituierten 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz
MXPA02000052A (es) Metodos y composiciones para el soporte, regeneracion y reparacion de tejidos conectivos.
DE69926357D1 (de) Vorbereitung eines medikaments zur behandlung von refluxösophagitis
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE272651T1 (de) Verbindungen mit wachstumshormon-freisetzender eigenschaft
UA29106A (uk) Спосіб лікування вібраційної хвороби

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties